{
    "organizations": [],
    "uuid": "64826fa2b23f413ef5ad9bce0cd0dd5b6a801727",
    "author": "",
    "url": "https://www.reuters.com/article/brief-ligand-enters-into-worldwide-omnia/brief-ligand-enters-into-worldwide-omniab-platform-license-agreement-with-ferring-pharmaceuticals-idUSFWN1PH0VB",
    "ord_in_thread": 0,
    "title": "BRIEF-Ligand Enters Into Worldwide Omniab Platform License Agreement With Ferring Pharmaceuticals",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 22, 2018 / 2:10 PM / Updated 7 minutes ago BRIEF-Ligand Enters Into Worldwide Omniab Platform License Agreement With Ferring Pharmaceuticals Reuters Staff \nJan 22 (Reuters) - Ligand Pharmaceuticals Inc: \n* LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH FERRING PHARMACEUTICALS \n* LIGAND PHARMACEUTICALS INC - ‍UNDER LICENSE, FERRING WILL BE ABLE TO USE FULL OMNIAB PLATFORM TO DISCOVER FULLY HUMAN MONO- AND BISPECIFIC ANTIBODIES​ \n* LIGAND PHARMACEUTICALS INC - ‍FERRING WILL BE RESPONSIBLE FOR ALL COSTS RELATED TO PROGRAMS​ \n* LIGAND PHARMACEUTICALS-WITH DEAL WITH FERRING, CO‍ ELIGIBLE TO RECEIVE ANNUAL PLATFORM ACCESS PAYMENTS, DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-22T16:08:00.000+02:00",
    "crawled": "2018-01-22T16:19:59.033+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "enters",
        "worldwide",
        "omniab",
        "platform",
        "license",
        "agreement",
        "ferring",
        "pharmaceutical",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "ligand",
        "pharmaceutical",
        "inc",
        "ligand",
        "enters",
        "worldwide",
        "platform",
        "license",
        "agreement",
        "ferring",
        "pharmaceutical",
        "ligand",
        "pharmaceutical",
        "inc",
        "license",
        "ferring",
        "able",
        "use",
        "full",
        "omniab",
        "platform",
        "discover",
        "fully",
        "human",
        "bispecific",
        "ligand",
        "pharmaceutical",
        "inc",
        "responsible",
        "cost",
        "related",
        "ligand",
        "deal",
        "ferring",
        "eligible",
        "receive",
        "annual",
        "platform",
        "access",
        "payment",
        "development",
        "regulatory",
        "milestone",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}